Understand the source comparison
Best Peptides for Plantar Fasciitis: Research Evidence Comparison
BPC-157 VEGFR-2 upregulation drives angiogenesis; fibroblast migration acceleration 200–500 mcg daily SC, near injury site Animal models + case reports; no RCTs Requires daily dosing; local administration preferred TB-500 Actin polymerization; endothelial cell
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGFR-2 upregulation drives angiogenesis; fibroblast migration acceleration
- 200–500 mcg daily SC, near injury site
- Animal models + case reports; no RCTs
- Requires daily dosing; local administration preferred
- TB-500
- Actin polymerization; endothelial cell migration; VEGF pathway activation
- 2–2.5 mg 2x/week for 4 weeks (loading), then 2 mg weekly
- Animal models; Phase 1 human safety data exists
- Systemic distribution; less frequent dosing
- GHK-Cu
- IL-6/TNF-alpha downregulation; TGF-beta activation; collagen type I synthesis
- 1–3 mg daily SC
- Wound healing RCTs; no plantar fascia-specific trials
- Injection site reactions in ~15%; avoid in copper metabolism disorders